Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $14.85. Crescent Biopharma shares last traded at $13.50, with a volume of 321,487 shares trading hands.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on CBIO shares. Wedbush began coverage on Crescent Biopharma in a report on Monday. They set an "outperform" rating and a $27.00 price target on the stock. TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a report on Friday, June 20th. Stifel Nicolaus began coverage on Crescent Biopharma in a report on Wednesday, June 25th. They set a "buy" rating and a $28.00 target price on the stock. Lifesci Capital raised Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price on the stock in a report on Wednesday, June 18th. Finally, Wall Street Zen raised Crescent Biopharma to a "sell" rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, two have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $25.67.
Get Our Latest Stock Analysis on Crescent Biopharma
Crescent Biopharma Price Performance
The firm has a market capitalization of $250.24 million, a PE ratio of -0.28 and a beta of 1.52.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Recommended Stories
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
